Lantern Pharma Inc. (LTRN)
3.53
0.22 (6.65%)
At close: Apr 02, 2025, 3:59 PM
3.47
-1.81%
After-hours: Apr 02, 2025, 07:56 PM EDT
6.65% (1D)
| Bid | 3.21 |
| Market Cap | 38.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.93 |
| PE Ratio (ttm) | -1.83 |
| Forward PE | -2.92 |
| Analyst | Hold |
| Ask | 3.53 |
| Volume | 26,294 |
| Avg. Volume (20D) | 84,721 |
| Open | 3.34 |
| Previous Close | 3.31 |
| Day's Range | 3.32 - 3.53 |
| 52-Week Range | 2.79 - 9.33 |
| Beta | 1.63 |
About LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 11, 2020
Employees 21
Stock Exchange NASDAQ
Ticker Symbol LTRN
Website https://www.lanternpharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for LTRN stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 608.22% from the latest price.
Stock Forecasts3 months ago
+4.27%
Lantern Pharma shares are trading higher after the...
Unlock content with
Pro Subscription
4 months ago
+0.95%
Lantern Pharma shares are trading higher after the company announced LP-184 received its second fast-track designation status from the FDA for the treatment of triple-negative breast cancer.
